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Combination therapy has been recommended to treat Pseudomonas aeruginosa infections worldwide. The
purpose of the present study was to determine the in vitro activities of piperacillin, cefepime, aztreonam,
amikacin, and ciprofloxacin alone and in combination against 100 clinical isolates of P. aeruginosa from
one medical center in southern Taiwan. The combination susceptibility assay was performed using the
checkerboard technique. The percentage of resistance of P. aeruginosa to single agents in our study was
relatively high for the Asia-Pacific area, except to aztreonam. Piperacillin plus amikacin exhibited the
highest potential for synergy (59/100) in this study. Moreover, a high percentage of synergism was also
noted with amikacin combined with cefepime (7/100) or aztreonam (16/100). The combination of two
beta-lactams, such as cefepime with piperacillin, and aztreonam with cefepime or piperacillin, showed
synergistic effects against some P. aeruginosa isolates. Although ciprofloxacin is a good anti-pseudomonal
agent, a very low potential for synergy with other antibiotics was demonstrated in this study. No antagonism
was exhibited by any combination in our study. Among piperacillin-resistant strains, there was synergy
with a beta-lactam plus amikacin, including the combination of piperacillin and amikacin. However, the
combination of two beta-lactams, such as piperacillin and cefepime or aztreonam, did not have any
synergistic activity against these strains. In summary, the combinations of amikacin with the tested beta-
lactams (piperacillin, aztreonam, cefepime) had a greater synergistic effect against P. aeruginosa, even
piperacillin-resistant strains, than other combinations. Understanding the synergistic effect on clinical
strains may help clinicians choose better empirical therapy in an area with high prevalence of multidrug-
resistant P. aeruginosa.
Key Words: Pseudomonas aeruginosa, antimicrobial combination, in vitro susceptibility
(Kaohsiung J Med Sci 2004;20:261–7)
Received: February 3, 2004    Accepted: April 14, 2004
Address correspondence and reprint requests to: Dr. Po-Liang Lu,
Division of Infectious Diseases, Department of Internal Medicine,
Kaohsiung Medical University, 100 Tzyou 1st Road, Kaohsiung 807,
Taiwan.
E-mail: d830166@cc.kmu.edu.tw
© 2004 Elsevier. All rights reserved.
Pseudomonas aeruginosa, one of the leading pathogens of
nosocomial infections around the world, has been one of
the most difficult to treat [1,2]. It contributes to major
infections in high-risk populations, particularly those who
have cancer or are mechanically ventilated [3,4]. Despite the
recent advances in antimicrobial therapy, P. aeruginosa
infections cause high morbidity and mortality, especially
among immunocompromised patients [5]. The development
of antimicrobial resistance, a major challenge for physicians
and hospitals worldwide, has been well documented with
monotherapy [6]. Consequently, combination therapy has
been generally recommended for P. aeruginosa infections, to
prevent development of antimicrobial resistance and harness
synergistic effects [7]. The combination of a beta-lactam and
an aminoglycoside has been the standard empirical therapy
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for P. aeruginosa for years [8]. Fluoroquinolones, especially
ciprofloxacin, have emerged recently as an alternative due
to their lower toxicity [9].
However, in the microbiology laboratory, susceptibility
is only tested with single antibiotics, which is often inade-
quate for multiresistant pathogens. Furthermore, the compa-
risons of in vitro synergism or antagonism among different
combinations against P. aeruginosa have not been reported
in Taiwan. Without this in vitro information, the choice of a
combination regimen can often only be made empirically,
which may result in a suboptimal treatment outcome.
In response to these challenges, we report here on the
first analyses of in vitro activities of various combinations
of several newly developed anti-pseudomonal agents on




A total of 100 consecutive, non-repetitive, clinical P. aeru-
ginosa isolates were collected from the clinical bacterio-
logy laboratory of Kaohsiung Medical University Hos-
pital, a 1,200-bed medical center in southern Taiwan, be-
tween September 1 and 30, 2001. Forty isolates were from
sputum specimens, 31 were from wounds, 16 were from
urine samples, eight were from blood specimens, and five
were from bile. Bacterial strains were stored at –70°C be-
fore testing.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by both the
agar dilution and disk diffusion tests, according to the
National Committee for Clinical Laboratory Standards
(NCCLS) [10,11]. For susceptibility testing by the agar
dilution method, the following antimicrobial agents were
obtained as standard reference powders of known potency
for laboratory use: piperacillin (Lederle Laboratories, Pearl
River, NY, USA), ciprofloxacin (Bayer Co, Leverkusen,
Germany), and aztreonam, amikacin, and cefepime (Bristol-
Myers Squibb Co, Princeton, NJ, USA). All drugs were
incorporated into Mueller-Hinton agar (BBL Microbiology
Systems, Cockeysville, MD, USA) in serial two-fold con-
centrations from 0.03 to 128 µg/mL. Three control strains,
Escherichia coli ATCC 35218 and ATCC 25922 and Pseu-
domonas aeruginosa ATCC 27853, were included in each
test run. Inoculated plates were incubated in ambient air
at 35°C for 16 to 18 hours. The minimal inhibitory con-
centration (MIC) of each antimicrobial agent was defined as
the lowest concentration that inhibited visible growth of the
organism on a plate.
Checkerboard assay
The anti-pseudomonal properties of nine combinations
of antimicrobial agents were determined using a two-
dimensional checkerboard agar dilution method [12]. The
nine combinations were: amikacin with ciprofloxacin,
piperacillin, cefepime, or aztreonam; aztreonam with
ciprofloxacin, cefepime, or piperacillin; and cefepime with
ciprofloxacin or piperacillin. Serial dilutions of two different
antimicrobial agents were mixed in Mueller-Hinton broth.
Inocula were prepared from colonies grown on Mueller-
Hinton agar plates after overnight culture. Bacterial
suspensions with turbidities equivalent to that of a 0.5 Mc-
Farland standard were prepared to yield a final inoculum of
5 × 105 colony-forming units (CFU)/mL. After incubation at
35°C for 24 hours, MICs were determined as the lowest
concentration at which there was no visible growth in
broth. The fractional inhibitory concentration (FIC) (the
ratio of the MIC of antibiotic A in the combination and the
MIC of antibiotic A alone) was calculated for each antibiotic
in each combination. The FIC for the combination was the
sum of the FICs for the two antibiotics. Of the FIC indices
calculated for all rows in the checkerboard, the minimum
value was the FIC index for that isolate. Synergism was
defined as when the FIC index was 0.5 or less, and anta-
gonism was defined as when the FIC index was more than
4. No interaction was defined as an FIC index between
0.5 and 4. The definition of the effect of the combination
of two antimicrobial agents was according to the latest
reported criteria [13]. Quality control strains were the
same as those described above.
RESULTS
The percentages of non-susceptible isolates for various
antimicrobial agents using the disk diffusion method were
as follows: moxalactam (95%), ceftriaxone (66%), piperacil-
lin (31%), ticarcillin/clavulanate (22%), gentamicin (17%),
ceftazidime (12%), aztreonam (12%), ciprofloxacin (9%),
piperacillin/tazobactam (9%), cefepime (9%), amikacin (7%),
and imipenem (5%). The MICs for, and susceptibilities to,
aztreonam, amikacin, ciprofloxacin, piperacillin, and cefepime
using the broth microdilution method are shown in Table 1.
The distribution of FICs of nine combinations of two
antimicrobial agents are shown in Table 2. Synergism was
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greatest with a combination of piperacillin and amikacin
(59%), followed by aztreonam plus amikacin (16%), and
cefepime with piperacillin (8%). No antagonism was seen
with any of the nine combinations. All four amikacin-
containing combinations had synergism in some isolates,
especially when in combination with beta-lactams (pip-
eracillin, cefepime, aztreonam).
Subgroup analysis for piperacillin-resistant
isolates
Twenty-two P. aeruginosa isolates were resistant to pip-
eracillin in our study. Of these, 9.1% were not susceptible
to amikacin, 36.4% to ciprofloxacin, 36.4% to cefepime,
and 40.9% to aztreonam. These non-susceptible rates are
significantly higher than those among piperacillin-
susceptible isolates (Fisher’s exact test; p = 0.039, p = 0.01,
p < 0.001, p < 0.001, respectively). The effects of combinations
of two antimicrobial agents on the 22 piperacillin-resistant
isolates are shown in Table 3. Amikacin showed synergy
with piperacillin for five strains (22.7%), while piperacillin
combined with cefepime or aztreonam did not reveal a
synergistic effect. Amikacin also had a synergistic effect on
some piperacillin-resistant isolates when combined with
the other two beta-lactams (cefepime or aztreonam).
DISCUSSION
Although combination therapy has been recommended for
P. aeruginosa infections for years, to date, no in vitro data
have been documented on its effect against clinical strains
isolated in Taiwan.
During the past decade, the increasing prevalence of
antimicrobial resistance among clinical isolates of P.
aeruginosa has been a critical issue in hospitals worldwide
[14–16]. Compared with the results of the worldwide
SENTRY antimicrobial surveillance program published
in 2002 [17], the prevalence of non-susceptible clinical iso-
lates in our study was relatively high for the Asia-Pacific
area, except for aztreonam (our study vs Asia-Pacific area
in SENTRY, 13% vs 19.1%), cefepime (14% vs 6.5%), pipera-
cillin (22% vs 14.5%), amikacin (7% vs 4.8%), and ciproflo-
xacin (19% vs 11.6%) (Table 1). The high resistance rate to
piperacillin in our single-agent susceptibility study might
Table 1. In vitro susceptibilities of 100 Pseudomonas aeruginosa isolates to five antimicrobial agents
MIC (µg/mL) Number of isolates
Antibiotic Range MIC50 MIC90 Susceptible Intermediate Resistant
Aztreonam 0.25–128 4 32 87 4 9
Amikacin 0.5–64 4 16 93 4 3
Ciprofloxacin 1–64 1 8 81 5 14
Piperacillin 1–128 8 128 78 – 22
Cefepime 0.5–128 4 16 86 6 8
MIC = minimum inhibitory concentration.
Table 2. Fractional inhibitory concentrations (FICs) of combinations of two antimicrobial agents for 100 clinical Pseudomonas
aeruginosa isolates
FIC Number of isolates
Range Median Mean SD FIC ≤ 0.5 0.5 < FIC ≤ 2 2 < FIC ≤ 4 FIC > 4
Amk-Cip 0.31–1.25 1.03 1.01 0.13 2 98 0 0
Amk-Pip 0.03–2.25 0.375 0.55 0.4 59 39 2 0
Amk-Fep 0.25–1.5 1 0.91 0.29 7 93 0 0
Fep-Pip 0.28–2 1.25 1.09 0.38 8 92 0 0
Fep-Cip 0.06–1.5 1.03 1.05 0.14 1 99 0 0
Atm-Amk 0.16–2 1.03 0.91 0.35 16 84 0 0
Atm-Cip 0.63–1.5 1.02 1.02 0.08 0 100 0 0
Atm-Fep 0.38–1.5 1.06 1.10 0.21 2 98 0 0
Atm-Pip 0.31–2.5 1.06 1.08 0.44 1 97 2 0
SD = standard deviation; Amk = amikacin; Cip = ciprofloxacin; Pip = piperacillin; Fep = cefepime; Atm = aztreonam.
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be attributable to the extended use of piperacillin plus an
aminoglycoside as the initial empirical combination therapy
against nosocomial infections (Annual Report of Infection
Control Committee, Kaohsiung Medical University
Hospital, unpublished data), mainly because piperacillin
has been the only first-line antimicrobial agent available
among the tested anti-pseudomonal agents in the
reimbursement system of the National Health Insurance.
The lower resistance rate to aztreonam might be attributed
to the lower consumption in our hospital, compared to
other antimicrobial agents (Annual Report of Infection
Control Committee, Kaohsiung Medical University
Hospital, unpublished data).
Against P. aeruginosa, the combination of a beta-lactam
and an aminoglycoside has been reported to have a relative-
ly high rate of synergy [18,19]. The combination of an
aminoglycoside (amikacin) and a beta-lactam (cefepime,
piperacillin, or aztreonam) exhibited synergy in a high
percentage of isolates in the present study (Table 2),
especially the combination of amikacin plus piperacillin.
Synergistic effects were found with combinations of
two beta-lactams, such as aztreonam plus cefepime or
piperacillin, in some P. aeruginosa isolates, although all
beta-lactams work through the inhibition of bacterial cell
wall synthesis. Although several animal models have
demonstrated antagonism against P. aeruginosa with beta-
lactam/beta-lactam combinations [20], Lister et al [21] and
Sader et al [22] have reported that aztreonam enhances
the antibacterial activity of cefepime, especially against
derepressed strains of P. aeruginosa. The synergism might
be partially attributed to the protection provided by az-
treonam to other beta-lactams in the extracellular envi-
ronment from extracellular beta-lactamase inactivation,
such as Bush group 1 chromosomal cephalosporinase [21].
With the diminished level of extracellular inactivation of
cefepime, more active cefepime would gain access to the
periplasmic space where aztreonam could provide pro-
tection as well. However, this synergy between cefepime
and aztreonam has not been consistently exhibited in other
studies [23,24].
Combination therapy is more important for infections
with piperacillin-resistant strains, which had a higher
percentage of multidrug resistance in the present study.
Therefore, we studied the synergistic potential of combi-
nation therapy against these resistant strains. The com-
bination of piperacillin and amikacin showed synergism
in five of the 22 piperacillin-resistant isolates. However, no
synergy was found with the combinations of piperacillin
with cefepime or aztreonam.
Recently, fluoroquinolones have become important in
the treatment of P. aeruginosa infections. Various anti-
microbial interactions have been documented in combina-
tion therapy including a fluoroquinolone. Synergism, in-
difference, or antagonism of fluoroquinolones have been
reported when combined with beta-lactams in different
studies [25–27]. In our study, a very low potential of synergy
was found with the combinations of ciprofloxacin and
cefepime (1/100) or aztreonam (0/100). Furthermore, cipro-
floxacin plus amikacin exhibited synergism in only two
of 100 strains. Among piperacillin-resistant strains, we
also found no synergistic effect with amikacin plus cipro-
floxacin. Some newly developed fluoroquinolones, such
as trovafloxacin and gatifloxacin, may exhibit synergy
with a beta-lactam in P. aeruginosa [27,28].
To date, there have been different criteria upon which to
interpret the antagonism of antimicrobial combinations
Table 3. Fractional inhibitory concentrations (FICs) of combinations of two antimicrobial agents for 22 piperacillin-resistant
Pseudomonas aeruginosa isolates
FIC Number of isolates
Range Median Mean SD FIC ≤ 0.5 0.5 < FIC ≤ 2 2 < FIC ≤ 4 FIC > 4
Amk-Cip 0.51–1.25 1.0 0.99 0.15 0 22 0 0
Amk-Pip 0.04–1.06 0.625 0.679 0.32 5 17 0 0
Amk-Fep 0.25–1.25 0.75 0.82 0.26 3 19 0 0
Fep-Pip 1.03–1.5 1.25 1.16 0.12 0 22 0 0
Fep-Cip 0.52–1.02 1.00 0.97 0.12 0 22 0 0
Atm-Amk 0.16–1.06 0.75 0.74 0.28 4 18 0 0
Atm-Cip 0.63–1.13 1.0 0.93 0.14 0 22 0 0
Atm-Fep 0.38–1.5 1.0 1.06 0.22 1 21 0 0
Atm-Pip 0.56–1.5 1.09 1.16 0.25 0 22 0 0
SD = standard deviation; Amk = amikacin; Cip = ciprofloxacin; Pip = piperacillin; Fep = cefepime; Atm = aztreonam.
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using the checkerboard method. Originally, synergism was
defined as an FIC index of 0.5 or less, and antagonism as
an FIC index of at least 2.0 [12]. However, several recent
publications recommend a stricter criterion to redefine an-
tagonism as an FIC index of more than 4.0 [13,29]. Using
this strict criterion, no antagonism was found in any combi-
nation tested in our study, although with amikacin plus
piperacillin, two strains had FIC indices between 2.0
and 4.0, and with aztreonam plus piperacillin, two strains
had an FIC index between 2.0 and 4.0.
Several methods are used to evaluate in vitro anti-
microbial combination effects, including the checkerboard
and time-kill methods [12]. The checkerboard method is the
best known and simplest. Although it is not able to provide
a more dynamic description of antimicrobial effect over
time, its results can easily be compared with most published
data. However, the results generated from these two meth-
ods do not correlate well [30,31]. Burgess et al, using the
time-kill method, demonstrated synergy more frequently
when a beta-lactam was combined with an aminoglycoside
than with a fluoroquinolone for P. aeruginosa [32].
In conclusion, combination therapy has been recom-
mended for P. aeruginosa infections, especially as there
is a high prevalence of drug resistance in Taiwan. Ami-
kacin plus piperacillin was the antibiotic combination with
a synergistic effect for most clinical P. aeruginosa isolates.
According to the greatest potential for synergy in our
study, amikacin plus cefepime and amikacin plus aztreo-
nam were also favorable combination therapies for most
P. aeruginosa infections, even those caused by piperacillin-
resistant strains. Combinations of two beta-lactams also
exhibited synergy for some P. aeruginosa isolates. Compared
with other combinations, combinations with ciprofloxacin
provide no further synergistic effect. Although there was
no concomitant investigation on clinical efficacy in our
study, these in vitro results might provide practical infor-
mation for the optimal choice of empirical combination
therapy against P. aeruginosa.
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